November 4, 2026- QuidelOrtho Corporation announced financial results for the third quarter ended September 27, 2026.
Key Third Quarter 2026 Results:
(all comparisons are to the prior year period)
- Total revenue was $619 million, a decrease of 12% both as reported and in constant currency. Excluding respiratory, China, and the U.S. Donor Screening business, total revenue grew 2% as reported and 3% in constant currency, reflecting the underlying strength of the business.
Labs revenue of $353 million declined 6% both as reported and in constant currency, primarily due to lower sales in China related to recently announced changes to In Vitro Diagnostics pricing. Outside China, Labs revenue grew 3% as reported and 4% in constant currency, driven by continued strength across the business.
Immunohematology revenue of $142 million was flat as reported and increased 1% in constant currency. Outside China, Immunohematology revenue grew 2% as reported and 3% in constant currency.
Point of Care revenue of $120 million declined 27% both as reported and in constant currency due to a softer respiratory season.
- GAAP net loss was $54 million; GAAP operating loss was $8 million; adjusted EBITDA was $148 million.
- GAAP net loss margin was 8.7%; GAAP operating loss margin was 1.2%; adjusted EBITDA margin was 23.9%.
- GAAP diluted loss per share was $0.78; adjusted diluted earnings per share (“EPS”) was $0.31.
- Operating cash flow was $20 million; free cash flow was $0.3 million.